See also: U.S. Guidelines for HIV Testing, Prevention, and Treatment; Starting HIV Treatment; Changing HIV Treatment Regimens; Salvage Treatment for HIV; and Comparing HIV Drug Regimens

Selected Recent Articles

• ViiV Begins Phase III Trial of Two-Drug HIV Regimen.  (August 2016, Poz)
• AIDS 2016: Undetectable with long-acting, user-friendly injectable HIV medications.  (August 2016, Beta Blog)
• Can a Two-Drug Treatment Regimen Keep HIV Under Control?  (August 2016, Beta Blog)
• Four-Day-Per-Week Treatment Maintains HIV Control for 48 Weeks.  (August 2016, TheBodyPro)
• Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise.  (August 2016, TheBodyPro)
• HIV Cure Research Strategies.  (July 2016, TheBodyPro)
• Nanoparticles containing dolutegravir demonstrate efficacy for PrEP delivery.  (July 2016, Healio)
• Dolutegravir plus lamivudine dual therapy works well as initial HIV treatment.  (July 2016, AIDSmap); related coverage from MedPage Today
• Long-acting injectable drugs work well for HIV maintenance therapy.  (July 2016, AIDSmap)
• Experimental Therapy Fails to Stop Viral Rebound Post-HIV Treatment Interruption.  (July 2016, Poz)
• Abbreviated ART passes phase 2/3 noninferiority trial in adolescents.  (July 2016, Healio)
• Strategies for simplifying ART regimens hold ‘considerable promise.’  (June 2016, Healio)
• Injectable antiretrovirals: The future of HIV management? (June 2016, Healio)
• Maintenance regimen of injected cabotegravir + rilpivirine advances through study.  (April 2016, Project Inform)
• CTLs: Stormtroopers of the Immune System.  (March 2016, amfAR)
• Dose-finding trials of antibody-based drugs for HIV prevention will start soon.  (February 2016, AIDSmap)
• Injectable long-acting cabotegravir shows promise as PrEP in early safety trial.  (February 2016, Poz); felated coverage from AIDSmap and abstract from 2016 Retrovirus Conference
• Innovations in antiretroviral therapy delivery.  (February 2016, Retrovirus Conference)
• Long-acting injectable cabotegravir + rilpivirine works well as HIV maintenance therapy.  (February 2016, AIDSmap); related coverage from Poz and TheBody)
• The HIV latent reservoir: Obstacles and strategies to a cure.  (February 2016, Retrovirus Conference)
• Tivicay/lamivudine regimen more cost-effective than standard ART.  (January 2016, Healio)
• It’s OK for HIV Salvage Regimens to Nix Nukes.  (January 2016, Poz)
• HIV salvage regimens can safely omit NRTIs, says US study.  (January 2016, AIDSmap)
• Switching to Two-Drug HIV Regimen Would Save Big Money.  (December 2015, Poz)
• Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings. (December 2015, AIDSmap)
• Another Two-Drug HIV Regimen Shows Promise.  (December 2015, Poz)
• Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART.  (November 2015, AIDSmap)
• First Studies Spur Confidence in New Ways to PrEP.  (October 2015, Beta Blog)
• Why Dolutegravir Might Get Us Closer to Ending AIDS: Next Step, Further Research.  (October 2015, HIV i-Base)
• Can dolutegravir dual therapy or monotherapy produce and maintain HIV suppression?  (October 2015, AIDSmap)
• Remarkable Results With Dolutegravir Monotherapy.  (October 2015, HIV i-Base)
• Rilpivirine + darunavir HIV maintenance regimen matches standard three-drug antiretroviral therapy.  (September 2015, AIDSmap)
• Maintenance HIV regimen of rilpivirine and boosted darunavir as effective as three-drug treatment in early results.  (July 2015, Project Inform.
• Effective Two-Drug HIV Regimen Sets Stage for Long-Acting Treatment.  (April 2015, Poz)
• Cabotegravir and rilpivirine effective for HIV maintenance therapy at 96 weeks.  (March 2015, AIDSmap)
• HIV maintenance regimen of cabotegravir and rilpivirine looks promising.  (March 2015, Project Inform)
• BREATHER Study’s novel dosing regimen of 5 days on/2 days off controls HIV levels in young people. (March 2015, Project Inform)
• Abbreviated ART noninferior to continuous ART in children with HIV.  (February 2015, Healio)
• Financial Incentives for Undetectable Viral Load Are Well Received.  (December 2014, Poz)
• Protease inhibitor monotherapy: darunavir/ritonavir less effective than three-drug therapy.  (November 2014, AIDSmap)
• Viral Rebound Is Significantly Delayed Among Some Who Interrupt HIV Treatment.  (October 2014, TheBodyPro)
• Janssen and ViiV Team Up for New Single-Tablet HIV Regimen.  (June 2014, Poz)
• Isentress + Prezista Is Safe, Effective as First-Line HIV Therapy.  (March 2014, Poz)
• Early Trial Paves the Way for Study of Long-Acting HIV Meds.  (March 2014, Poz)
• Long-Acting HIV Drugs for Maintenance and PrEP. (March 2014, Beta Blog)
• 3 Regimens Hold HIV in Check Without Efavirenz. (March 2014, MedPage Today)
• Novel two-drug maintenance combination works at least as well as triple therapy: stage set for long-lasting injectable formulation.  (March 2014, AIDSmap)
• Raltegravir plus boosted darunavir shown to be safe and effective for first-line ART.  (March 2014, AIDSmap)
• Trial Bodes Well for Long-Acting HIV Drugs. (March 2014, MedPage Today)
• Building a Better HIV Drug: Nano-Formulated Medicines.  (December 2013, TheBodyPro)
• Long-Acting HIV Drugs Could Extend Lives of Low Adherers.  (November 2013, Poz)
• Once-daily raltegravir effective as maintenance therapy.  (October 2013, AIDSmap)
• New HIV Drug Class Shows Promise.  (October 2013, Poz)
• Kaletra and Epivir Dual Therapy Works as Well as Triple Combo.  (October 2013, Poz)
• Future HIV care will include both novel antiretroviral drugs and new treatment strategies.  (October 2013, AIDSmap)
• Dual therapy with Kaletra and 3TC works well regardless of viral load.  (October 2013, AIDSmap)
• Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?  (October 2013, TheBodyPro)
• Targeting Reactivated HIV Using Natural Killer Cells: Another Potential Cure Strategy.  (September 2013, TheBodyPro)
• Once-a-Month HIV Meds Show Promise in Early Trial.  (July 2013, Poz)
• Studies look at bone changes during second-line therapy, fractures, and HIV- and HCV-related bone loss.  (July 2013, AIDSmap)
• Kaletra monotherapy achieves ‘satisfactory’ levels of HIV suppression during pregnancy.  (June 2013, AIDSmap)
• Can people with resistant HIV omit NRTIs when switching from a failing regimen?  (March 2013, AIDSmap)